menu search

PRGO / With a Big Catalyst in Hand, Is Perrigo Company a Buy?

With a Big Catalyst in Hand, Is Perrigo Company a Buy?
Perrigo's birth control pill, Opill, can now be sold without a prescription. It'll likely start to nibble on the market shares of most other contraceptive methods. Read More
Posted: Jul 21 2023, 08:50
Author Name: The Motley Fool
Views: 112519

PRGO News  

FDA warns three baby-formula makers about production violations

By Market Watch
August 30, 2023

FDA warns three baby-formula makers about production violations

The U.S. Food and Drug Administration said Wednesday it has sent warning letters to three baby-formula makers as part of what the agency called enhanc more_horizontal

The Prognosis For Perrigo

By Seeking Alpha
August 30, 2023

The Prognosis For Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions after recently divesting its prescription businesses. Perrigo stock is rea more_horizontal

Perrigo to Attend Upcoming Consumer Investor Conferences

By PRNewsWire
August 24, 2023

Perrigo to Attend Upcoming Consumer Investor Conferences

DUBLIN , Aug. 24, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that CFO E more_horizontal

Perrigo Company plc (PRGO) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 8, 2023

Perrigo Company plc (PRGO) Q2 2023 Earnings Call Transcript

Perrigo Company plc (NYSE:PRGO ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Brad Joseph - Vice President, Investo more_horizontal

Perrigo (PRGO) Beats on Q2 Earnings & Sales, Reiterates '23 View

By Zacks Investment Research
August 8, 2023

Perrigo (PRGO) Beats on Q2 Earnings & Sales, Reiterates '23 View

Perrigo (PRGO) reports encouraging second-quarter 2023 results. Management reaffirms the financial guidance for 2023. more_horizontal

Perrigo (PRGO) Q2 Earnings and Revenues Beat Estimates

By Zacks Investment Research
August 8, 2023

Perrigo (PRGO) Q2 Earnings and Revenues Beat Estimates

Perrigo (PRGO) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings more_horizontal

Perrigo to Release Second Quarter 2023 Financial Results and Present at an Industry Growth Conference

By PRNewsWire
July 25, 2023

Perrigo to Release Second Quarter 2023 Financial Results and Present at an Industry Growth Conference

DUBLIN , July 25, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it pl more_horizontal

With a Big Catalyst in Hand, Is Perrigo Company a Buy?

By The Motley Fool
July 21, 2023

With a Big Catalyst in Hand, Is Perrigo Company a Buy?

Perrigo's birth control pill, Opill, can now be sold without a prescription. It'll likely start to nibble on the market shares of most other contracep more_horizontal


Search within

Pages Search Results: